StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Stock remains constrained by questions & remaining catalyst pathway'
October 13, 2026 8:59 AM
Bernstein SocGen Group analyst Courtney Breen reiterated a Market Perform rating and $61.00 price target on Bristol-Myers Squibb Co. (NYSE ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
